Management of MRSA Infections

General Principles

The Infectious Diseases Society of America recommends treating MRSA infections for varying durations based on the type of infection, with skin and soft tissue infections typically requiring 7-14 days of therapy, uncomplicated bacteremia requiring at least 2 weeks, complicated bacteremia requiring 4-6 weeks, endocarditis requiring 6 weeks, and osteomyelitis requiring a minimum of 8 weeks 1, 2, 3

The World Society of Emergency Surgery recommends 7-14 days of therapy for MRSA skin and soft tissue infections, with duration based on clinical response 1, 4
Uncomplicated infections require shorter courses of 5-10 days 5
Clinical reassessment within 48-72 hours is essential to ensure appropriate response and adjust duration accordingly 5
IV to oral switch should occur when clinical stability criteria are met (afebrile, improving local signs, tolerating oral intake) 1, 4

The Infectious Diseases Society of America recommends treating uncomplicated MRSA bacteremia for at least 2 weeks 3, 2
Uncomplicated bacteremia is defined as: exclusion of endocarditis, no implanted prostheses, negative follow-up blood cultures obtained 2-4 days after initial positive cultures, defervescence within 72 hours of initiating therapy, and no evidence of metastatic infection 3, 2
Vancomycin or daptomycin 6 mg/kg/dose IV once daily are the recommended agents 3, 2
Complicated bacteremia requires 4-6 weeks of treatment, depending on the extent of infection 3, 2

The Infectious Diseases Society of America recommends treating MRSA infective endocarditis for 6 weeks with IV vancomycin or daptomycin 3, 2
Daptomycin dosing is 6 mg/kg/dose IV once daily, though some experts recommend higher dosages of 8-10 mg/kg/dose 3, 2
Echocardiography is recommended for all adult patients with MRSA bacteremia to rule out endocarditis 3, 2

The Infectious Diseases Society of America recommends treating MRSA osteomyelitis for a minimum of 8 weeks 6, 5
Oral options include TMP-SMX 4 mg/kg/dose twice daily combined with rifampin 600 mg once daily, linezolid 600 mg twice daily, or clindamycin 600 mg every 8 hours 5
Surgical debridement and drainage of associated soft-tissue abscesses should always be performed 3

The Infectious Diseases Society of America recommends treating MRSA septic arthritis for 3-4 weeks 6
Drainage or debridement of the joint space must always be performed 6
Antibiotic choices should follow recommendations for osteomyelitis 6

The Infectious Diseases Society of America recommends treating early-onset prosthetic joint infections with device retention for 2 weeks with parenteral therapy plus rifampin, followed by rifampin plus an oral agent for 3 months (hips) or 6 months (knees) 6
Prompt debridement with device retention is essential 6
Late-onset infections (>30 days after implant) require device removal whenever feasible 6

The Infectious Diseases Society of America recommends that duration of treatment for MRSA pneumonia depends on the extent of infection and clinical response 6, 5
Oral clindamycin 600 mg three times daily or linezolid 600 mg twice daily can be used for outpatient management 5
For pneumonia complicated by empyema, antimicrobial therapy must be used in conjunction with drainage procedures 3, 2

Never use beta-lactam antibiotics alone for MRSA, as they are completely ineffective 5
Never use rifampin as monotherapy, as resistance develops rapidly 6, 5
Failure to drain abscesses leads to treatment failure regardless of antibiotic choice 5
Always obtain follow-up blood cultures 2-4 days after initial positive cultures to document clearance in bacteremia 3, 2
Always perform echocardiography in adult patients with MRSA bacteremia to exclude endocarditis 3, 2

Immediate removal of any infected foreign body or device is essential to achieve source control in MRSA bacteremia with septic emboli. 7
Inadequate source control is identified as the most common cause of treatment failure; therefore, reassessment of source control should be performed when bacteremia persists despite therapy. 7

A clinical reassessment should be performed within 48–72 hours of initiating antimicrobial therapy to confirm an appropriate therapeutic response. 7
Persistence of fever or worsening organ dysfunction beyond 48–72 hours mandates prompt evaluation of source‑control adequacy. 7

In patients receiving oral anticoagulants at the time of MRSA septic emboli diagnosis, the oral agent should be discontinued and substituted with intravenous heparin to reduce the risk of hemorrhagic complications from embolic events. 8